Rous sarcoma virus v-src oncogene mRNA (v-src mRNA)

v-src mRNA is the messenger RNA transcript of the v-src oncogene, the first oncogene identified, originating from the Rous Sarcoma Virus (RSV) (Stehelin et al., Nature, 1976). This mRNA encodes the v-Src protein, a non-receptor tyrosine kinase that is constitutively active because it lacks the C-terminal inhibitory phosphorylation site (Tyr527) present in its cellular homolog, c-Src (Hunter, Cell, 1987). The translation of v-src mRNA leads to the production of a kinase that drives malignant transformation by phosphorylating various cellular substrates involved in growth and adhesion (Parsons & Parsons, CA: A Cancer Journal for Clinicians, 2004). Historically, v-src mRNA was one of the first targets for antisense technology, where synthetic oligonucleotides were used to inhibit viral replication and cell transformation (Zamecnik & Stephenson, PNAS, 1978). In modern research, RNA interference (RNAi) is frequently employed to silence v-src mRNA to study its role in oncogenic signaling pathways (Bromberg et al., Molecular and Cellular Biology, 1998). While clinical oncology primarily targets the human Src protein with small-molecule inhibitors like dasatinib, v-src mRNA remains a critical tool in understanding the molecular basis of cancer and developing nucleic acid-based therapies. The primary challenge in targeting v-src mRNA is ensuring specificity to avoid interfering with the essential physiological functions of the highly homologous cellular c-src mRNA.

Other names

Viral src mRNApp60v-src mRNARSV v-src mRNAv-src transcript

Inhibition of translation or degradation of mRNA through antisense binding or RNA interference (RNAi), preventing the production of the constitutively active v-Src tyrosine kinase.